Intrauterine Devices: A Review

Chinmaya Keshari Sahoo; Amiyakanta Mishra; D. Venkata Ramana; Jimidi Bhaskar

doi:10.5958/0975-4377.2020.00028.2

Research Journal of Pharmaceutical Dosage Forms and Technology

ISSN

0975-4377 (Online)
0975-234X (Print)

Submit Article

Intrauterine Devices: A Review

Author(s): Chinmaya Keshari Sahoo, Amiyakanta Mishra, D. Venkata Ramana, Jimidi Bhaskar

Email(s): sahoo.chinmaya83@gmail.com

DOI: 10.5958/0975-4377.2020.00028.2

Address: Chinmaya Keshari Sahoo1, Amiyakanta Mishra1, D. Venkata Ramana2, Jimidi Bhaskar3
1Department of Pharmaceutics, College of Pharmaceutical Sciences (Affiliated to BPUT), Bidyaniketan, Marine Drive Road, Baliguali, Puri, Odisha.
2Department of Pharmaceutical Technology, Samskruti College of Pharmacy, Kondapur, Ghatkesar, Medchal, Telangana, India.
3Department of Pharmaceutics, KLR Pharmacy College, Paloncha Bhadradri, Kothagudem, Telangana.
*Corresponding Author

Published In: Volume - 12, Issue - 3, Year - 2020

View HTML

View PDF

ABSTRACT:
An intra-uterine device is a special device that fits inside of the uterus. Intrauterine contraceptive device (IUD) is the most commonly used method of contraception in many countries. The IUDs are a long-acting reversible method of contraception. Despite the availability of many generations of IUDs with variable shapes and configurations, side effects and complications are frequent. Evidence-based practices have increased the number of women who are medically eligible for IUDs and have enabled more rapid access to the methods. Currently hormonal IUDs are available in the market. Each IUD is extremely effective, convenient, and safe. The newer IUDs have been tested in populations not usually included in clinical trials and provide reassuring answers to older concerns about IUD use in these women, including information about expulsion, infection, and discontinuation. On the other hand, larger surveillance studies have provided new estimates about the risks of complications such as perforation, especially in postpartum and breastfeeding women.

Keywords:

Cite this article:
Chinmaya Keshari Sahoo, Amiyakanta Mishra, D. Venkata Ramana, Jimidi Bhaskar. Intrauterine Devices: A Review. Res. J. Pharma. Dosage Forms and Tech.2020; 12(3):162-168. doi: 10.5958/0975-4377.2020.00028.2

Cite(Electronic):
Chinmaya Keshari Sahoo, Amiyakanta Mishra, D. Venkata Ramana, Jimidi Bhaskar. Intrauterine Devices: A Review. Res. J. Pharma. Dosage Forms and Tech.2020; 12(3):162-168. doi: 10.5958/0975-4377.2020.00028.2 Available on: https://www.rjpdft.com/AbstractView.aspx?PID=2020-12-3-5

REFERENCES:

1. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol. 2011; 118(1):184-196.

2. United Nations Dev. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1997; 56(6):341–352.

3. Thonneau PF, Almont T. Contraceptive efficacy of intrauterine devices. Am J Obstet Gynecol. 2008;198(3):248–253.

4. Ortiz ME, Croxatto HB. The mode of action of IUDs. Contraception. 1987;36(1):37–53.

5. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404.

6. Sivin I, Stern J, Diaz S, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am J Obstet Gynecol. 1992;166(4):1208-1213.

7. Nelson AL, Massoudi N. New developments in intrauterine device use: focus on the US. Open Access Journal of Contraception,2016;7:127-141.

8. Trussell J. Update on and correction to the cost effectiveness of contra¬ceptives in the United States. Contraception. 2012;85(2):218.

9. Stanford JB, Mikolajczyk RT. Mechanisms of action of intrauterine devices: update and estimation of postfertilization effects. Am J Obstet Gynecol. 2002; 187(6):1699-1708.

10. Alvarez F, Brache V, Fernandez E, et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril. 1988; 49(5):768-773.

11. Johnson BA. Insertion and removal of intrauterine devices. Am Fam Phy¬sician. 2005; 71(1):95-102.

12. Grimes DA, Lopez LM, Schulz KF, Van Vliet HA, Stanwood NL. Immedi¬ate post-partum insertion of intrauterine devices. Cochrane Database Sys Rev. 2010;(5) CD003036.

13. Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol. 2010;116(5):1079-1087.

14. Celen S, Möröy P, Sucak A, Aktulay A, Danıs¸ man N. Clinical outcomes of early postplacental insertion of intrauterine contraceptive devices. Contraception. 2004; 69(4):279-282.

15. Çelen S, S¸ucak A, Yıldız Y, Danıs¸ man N. Immediate postplacental inser¬tion of an intrauterine contraceptive device during cesarean section. Contraception. 2011; 84(3):240-243.

16. International Medical Advisory Panel. IMAP statement on intrauterine devices. IPPF Med Bull. 2003;37(2):1-4.

17. Tyler CP, Whiteman MK, Zapata LB, Curtis KM, Hillis SD, Marchbanks PA. Health care provider attitudes and practices related to intrauterine devices for nulliparous women. Obstet Gynecol. 2012;119(4):762-771.

18. Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception. 2007;75(6 suppl):S8-S11.

19. Paterson H, Ashton J, Harrison-Woolrych M. A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand ado¬lescents. Contraception. 2009;79(6):433-438.

20. Veldhuis HM, Vos AG, Lagro-Janssen AL. Complications of the intra¬uterine device in nulliparous and parous women. Eur J Gen Pract. 2004;10(3):82-87.

21. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical per¬formance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Con¬traception. 2004;69(5):407-412.

22. Centers for Disease Control and Prevention. U.S. Medical eligi¬bility criteria for contraceptive use, 2010. MMWR Recomm Rep. 2010; 59(RR-4):1-86.

23. Campbell SJ, Cropsey KL, Matthews CA. Intrauterine device use in a high-risk population: experience from an urban university clinic. Am J Obstet Gynecol. 2007; 197(2): 193. e1-193.e6.

24. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception. 2006; 73(2):145-153.

25. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting revers¬ible contraception. N Engl J Med. 2012; 366(21):1998-2007.

26. Tavakolian S, Doulabi MA, Baghban AA, Mortazavi A, Ghorbani M. Lidocaine-prilocaine cream as analgesia for IUD insertion: a prospective, randomized, controlled, triple b Blinded study. Glob J Health Sci. 2015;7(4):399–404.

27. United Nations Dev. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1997;56(6):341–352.

28. Thonneau PF, Almont T. Contraceptive efficacy of intrauterine devices. Am J Obstet Gynecol. 2008;198(3):248–253.

29. Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device. Int J Womens Health. 2010; 2:211–220.

30. Bilian X. Chinese experience with intrauterine devices. Contraception. 2007;75(6 suppl): S31–S34.

31. Imai A, Matsunami K, Takagi H, Ichigo S. Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review. Clin Exp Obstet Gynecol. 2014;41(5):495–498.

32. Bahamondes L, Petta CA, Fernandes A, Monteiro I. Use of the levonorgestrel- releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception. 2007;75(6 suppl): S134–S139.

33. Kim MK, Seong SJ, Kim JW, et al. Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: a Korean gynecologic-oncology group study. Int J Gynecol Cancer. 2016; 26(4):711–715.

34. Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N. Levonorgestrelreleasing intrauterine system for atypical endometrial hyperplasia. Cochrane Database Syst Rev. 2013; 6:CD009458.

35. Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(3):625–632.

36. Kaunitz AM, Inki P. The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review. Drugs. 2012;72(2):193–215.

37. Eisenberg DL, Schreiber CA, Turok DK, et al; ACCESS IUS Investigators. Three-year efficacy and safety of a new 52-mg levonorgestrel releasing intrauterine system. Contraception. 2015;92(1):10–16.

38. Creinin MD, Jansen R, Starr RM, et al. Levonorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system. Contraception. Epub 2016.

39. Bahamondes MV, Monteiro I, Castro S, Espejo-Arce X, Bahamondes L. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system. Hum Reprod. 2010;25(5):1158–1164.

40. Mawet M, Nollevaux F, Nizet D, et al. Impact of a new levonorgestrel intrauterine system, Levosert, on heavy menstrual bleeding: results of a one-year randomized controlled trial. Eur J Contracept Reprod Health Care. 2014;19(3):169–179.

Recomonded Articles:

A Brief Review on Intra-Uterine Drug Delivery Systems

Author(s): Suyash Ingle, Varsha Tegeli, Akshay Javalgikar, Vinod Matole, Lagmanna koli, Avinash Birajdar, Saurabh Nangare, Sagar Adlinge, Swaminath Ramanshetti, Akhil Patil, Yash Kothari, Pandurang Choure, Aaqueeb Mangalgiri, Sneha Ubale, Vaishnavi Dulange, Bhavana habib, Jyoti Mittha

DOI: 10.5958/0975-4377.2021.00013.6 Access: Open Access Read More

Preparation and Evaluation of Ginger Mouth Gargle

Author(s): Sana Fathima, M. Venkataswamy, V. Harshitha, G. Laxmi Prasanna, Farheen Sulthana, Ashwini Patlolla

DOI: 10.5958/0975-4377.2019.00011.9 Access: Open Access Read More

A Systematic Review on COVID 19 Treatment and Management

Author(s): Isha Shah, Nensi Raytthatha, Jigar Vyas, Umesh Upadhyay

DOI: 10.52711/0975-4377.2021.00039 Access: Open Access Read More

Medicinal Plants used for the Treatment of Bacterial Meningitis

Author(s): Chikoti Sneha Priya, M. Venkataswamy, Gandla Harshini, Pindrathi Pravalika, Sandhya Mandadi, Jahnavi Bandla

DOI: 10.5958/0975-4377.2019.00040.5 Access: Open Access Read More

Development of Topical Herbal Gel of Berberine Hydrochloride for the Treatment of Psoriasis

Author(s): Shivi Sondhi, Navdeep Singh, Kamya Goyal, Shammy Jindal

DOI: 10.5958/0975-4377.2021.00003.3 Access: Open Access Read More

Intrauterine Devices: A Review

Author(s): Chinmaya Keshari Sahoo, Amiyakanta Mishra, D. Venkata Ramana, Jimidi Bhaskar

DOI: 10.5958/0975-4377.2020.00028.2 Access: Open Access Read More

Pharmacosomes- An Immense Potential Vesicular Constructs

Author(s): Selvaraju K., Vengadesh Prabhu K., Karthick K., Padma Preetha J., Arul Kumaran K.S.G.

DOI: Access: Open Access Read More

Antioxidant and Free Radical Scavenging Activity Azima tetracantha lam

Author(s): Muthukumaran P., Abirami C. , Priyatharsini

DOI: Access: Open Access Read More

Effect of Solid Dispersion Technique on Improving the Solubility of Roxithromycin

Author(s): K Ravi Sankar, NL Prasanthi, SS Manikiran, N Rama Rao

DOI: Access: Open Access Read More

Pharmacoepidemiology of Severe Systemic Infection and Need of Netilmicin Monotherapy or Combination Therapy: Systemic Review and Meta- Analysis

Author(s): Akhilesh Gupta, Swati Rawat, Prabhanshu Gupta

DOI: 10.5958/0975-4377.2017.00018.0 Access: Open Access Read More

Target Retentive Biodegradable Periodontal Disks for Simultaneous Extended Release of Metronidazole and Doxycycline: Formulation Consideration

Author(s): Gaurav Tiwari, Ruchi tiwari, Awani K Rai

DOI: Access: Open Access Read More

Research Journal of Pharmaceutical Dosage Forms and Technology (RJPDFT) is an international, peer-reviewed journal, devoted to pharmaceutical sciences. ...... Read more >>>

RNI: Not Available
DOI: 10.5958/0975-4377